IBI306 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
79	Homozygous familial hypercholesterolemia	2

79. Homozygous familial hypercholesterolemia

---

Clinical trials : 142 /  Drugs : 114 - (DrugBank : 29) / Drug target genes : 9 - Drug target pathways : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04948008 (ClinicalTrials.gov)	November 5, 2019	29/6/2021	Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia	A Seamless Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia in China	Familial Hypercholesterolemia - Homozygous;Lipid Metabolism Disorders;Proprotein Convertase Subtilisin/Kexin 9	Biological: IBI306	Shenzhen People's Hospital	NULL	Recruiting	18 Years	80 Years	All	8	Phase 2/Phase 3	China
2	NCT04031742 (ClinicalTrials.gov)	September 29, 2019	22/7/2019	A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia	Phase 2b/3 Study to Assess the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia. Part 1 - Open-label, Two-arm, Multicenter Pilot Study to Evaluate Efficacy and Safety of IBI 306 in Subjects With Homozygous Familial Hypercholesterolemia. Part 2 - Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of IBI 306 in Subjects With Homozygous Familial Hypercholesterolemia	Homozygous Familial Hypercholesterolemia	Biological: IBI306	Innovent Biologics (Suzhou) Co. Ltd.	NULL	Recruiting	18 Years	80 Years	All	30	Phase 2/Phase 3	China